SAS Output

22-SEP-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

73% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1558 1036 66% 1426 -131 1325 -233
ERLYTX 76 178 234% 245 169 216 140
GI 476 159 33% 219 -257 215 -261
GU 450 328 73% 451 1 470 20
GYN 57 0 0% 0 -57 0 -57
LEUK 150 55 37% 75 -74 80 -70
LUNG 524 252 48% 347 -176 340 -184
LYMPH 172 4 2% 5 -166 8 -164
MELAN 55 814 1480% 1121 1066 1076 1021
MMYEL 147 52 35% 71 -75 81 -66
OTHER 0 23   31 31 34 34
Total 3665 2901   3991 331 3845 180

22-SEP-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

73% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 1   1 1 1 1
BREAST 37 22 59% 30 -6 24 -13
CCD 0 1156   1592 1592 1579 1579
GU 0 0   0 0 0 0
LEUK 69 4 6% 5 -63 5 -64
LUNG 43 407 947% 560 517 573 530
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 11   15 15 12 12
PREV 0 61   84 84 79 79
SURV 0 60   82 82 72 72
SXQOL 878 12 1% 16 -861 30 -848
Total 1172 1734   2385 1216 2375 1203

22-SEP-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

73% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 1   1 1 1 1
BREAST 1595 1058 66% 1457 -137 1349 -246
CCD 0 1156   1592 1592 1579 1579
ERLYTX 76 178 234% 245 169 216 140
GI 476 159 33% 219 -257 215 -261
GU 450 328 73% 451 1 470 20
GYN 57 0 0% 0 -57 0 -57
LEUK 219 59 27% 81 -137 85 -134
LUNG 567 659 116% 907 340 913 346
LYMPH 225 4 2% 5 -219 8 -217
MELAN 55 814 1480% 1121 1066 1076 1021
MMYEL 239 52 22% 71 -167 81 -158
OTHER 0 34   46 46 46 46
PREV 0 61   84 84 79 79
SURV 0 60   82 82 72 72
SXQOL 878 12 1% 16 -861 30 -848
Total 4837 4635   6378 1546 6220 1383

22-SEP-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

73% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1012 434 43% 597 -414 534 -478
ERLYTX 76 121 159% 166 90 159 83
GI 418 120 29% 165 -252 169 -249
GU 375 236 63% 325 -49 326 -49
GYN 57 0 0% 0 -57 0 -57
LEUK 122 42 34% 57 -64 64 -58
LUNG 441 170 39% 234 -206 227 -214
LYMPH 129 4 3% 5 -123 8 -121
MELAN 55 426 775% 586 531 563 508
MMYEL 85 52 61% 71 -13 81 -4
OTHER 0 23   31 31 34 34
Total 2770 1628   2237 -526 2165 -605

22-SEP-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

73% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 10 22 220% 30 20 24 14
CCD 0 1011   1392 1392 1434 1434
GU 0 0   0 0 0 0
LEUK 69 4 6% 5 -63 5 -64
LUNG 30 287 957% 395 365 376 346
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 11   15 15 12 12
PREV 0 49   67 67 60 60
SURV 0 36   49 49 46 46
SXQOL 740 12 2% 16 -723 30 -710
Total 994 1432   1969 977 1987 993

22-SEP-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

73% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1022 456 45% 628 -393 558 -464
CCD 0 1011   1392 1392 1434 1434
ERLYTX 76 121 159% 166 90 159 83
GI 418 120 29% 165 -252 169 -249
GU 375 236 63% 325 -49 326 -49
GYN 57 0 0% 0 -57 0 -57
LEUK 191 46 24% 63 -127 69 -122
LUNG 471 457 97% 629 158 603 132
LYMPH 182 4 2% 5 -176 8 -174
MELAN 55 426 775% 586 531 563 508
MMYEL 177 52 29% 71 -105 81 -96
OTHER 0 34   46 46 46 46
PREV 0 49   67 67 60 60
SURV 0 36   49 49 46 46
SXQOL 740 12 2% 16 -723 30 -710
Total 3764 3060   4208 451 4152 388

22-SEP-2017 18:11

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

73% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2017
Accrual
to date
Percentage
of Base
Accrual
Projected
2017
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 65 878 1351% 1209 1144 1144 1079
CCD 0 1156   1592 1592 1579 1579
GI 81 24 30% 33 -47 38 -43
GU 215 54 25% 74 -140 66 -149
LEUK 0 4   5 5 5 5
LUNG 53 79 149% 108 55 128 75
LYMPH 7 1 14% 1 -5 3 -4
MELAN 0 743   1023 1023 984 984
MMYEL 0 52   71 71 81 81
OTHER 0 18   24 24 28 28
PREV 0 61   84 84 79 79
SURV 0 60   82 82 72 72
SXQOL 878 12 1% 16 -861 30 -848
Total 1299 3142   4322 3027 4237 2938

22-SEP-2017 18:11

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

The REPORT Procedure

Detailed and/or summarized report

Table 1

Comm. Phase Study Stat
Center
Open
Date
Months
Open
Total
Regs
Accrual
Goal
Monthly
Accrual
Rate
Date of
Expected Closure or
Temporary Closure
    NRGBR002 NRG     1      
BREAST II S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 SWOG 07JUL2016:00:00:00 14 135 333 14.3 Oct-2018
  III A011106 Breast, Neoadj, ALTERNATE study ALLIANCE 15FEB2014:00:00:00   49   2.8  
    A011202 Breast, Nodal XRT +/- ALND ALLIANCE     54      
    A011401 Breast, adj, Stage II/III HER2-, weight loss ALLIANCE 29AUG2016:00:00:00   74   8.5  
    A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo ALLIANCE 08DEC2016:00:00:00   14   2.2  
    B51 Breast, Regional Nodal XRT NRG     18      
    B55 Brst, Adj Olaparib for BRCA,TNBC NRG 03JUL2014:00:00:00   18   0.5  
    E2112 Brst,Adv,Exemestane+/-Entinostat ECOG-ACR 02JAN2014:00:00:00   39   1.7  
    NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG 22JAN2015:00:00:00   42   2.5  
    S1007 Breast,Adj,N1,Endocrine+/-Chemo SWOG 15JAN2011:00:00:00 80 5047 4000 43.0 Sep-2015
    S1207 Brst,Adj,Endocrine+/-Everolimus SWOG 03SEP2013:00:00:00 48 1356 1900 35.8 Dec-2018
    S1222 Brst,Fulv. +/- Ever. +/- Anastr. SWOG 09MAY2014:00:00:00   37 840   Feb-2015 Temp Close
    S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) SWOG 15NOV2016:00:00:00 10 66 1000 10.2 Apr-2025
  OTHER A221405 Breast, ET interruption, Pregnancy Outcomes ALLIANCE 15OCT2015:00:00:00   2   0.3  
    E1Z11 Brst,Genetic Predictors of AIMSS ECOG-ACRIN 10MAY2013:00:00:00   144   1.0  
CCD III A011104 Preoperative Breast MRI ALLIANCE 21FEB2014:00:00:00   10   0.5  
    S1415CD TrACER CSF Standing Order Intervention for FN SWOG 01SEP2016:00:00:00 12 895 3960 110.3 Dec-2019
  OTHER S1417CD Colorectal, Cost Cohort Study SWOG 13MAY2016:00:00:00 16 106 374 12.5 Jun-2019
ERLYTX II A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 06AUG2015:00:00:00   5   0.0  
    S1609 Rare Tumor, Comb Nivo/Ipi SWOG 13JAN2017:00:00:00 8 124 636 18.3 Dec-2019
  II-III A071102 GBM, adj TMZ +/- Veliparib ALLIANCE 19SEP2014:00:00:00   37   0.0  
    ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) COG 16MAY2014:00:00:00   4   0.3  
  OTHER EAY131 MATCH ECOG-ACR 12AUG2015:00:00:00   97   5.3  
GI II A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT ALLIANCE 01DEC2016:00:00:00   8   1.3  
    EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo ECOG-ACRIN 29JAN2016:00:00:00   1   0.0  
    EA2142 GI NEC, Adv G3, EP vs TMZ + CAP ECOG-ACRIN 06NOV2015:00:00:00   4   0.5  
    NRGGI002 Rectal, Ph II, Sensitization using TNT NRG 12OCT2016:00:00:00   2   0.2  
    S1505 Panc,Resect, Perioperative Chemo SWOG 12OCT2015:00:00:00 23 92 112 2.2 Jun-2018
    S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 SWOG 01SEP2016:00:00:00 12 88 143 11.5 Jan-2018
  II-III N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX ALLIANCE 13JAN2012:00:00:00   129   3.3  
  III R0848 Panc, Adj, Erlotinib v ChemoRT NRG 01MAR2014:00:00:00   20   0.0  
GU II EA8141 UTUC, HG, Chemo then Surg ECOG-ACR 27JAN2015:00:00:00   8   0.3  
    S1314 Blad, COXEN Neoadj. Chemo + Cyst SWOG 11JUL2014:00:00:00 38 224 230 9.3 Sep-2017
    S1500 pRCC,Adv, Sunitinib vs MET inhib SWOG 05APR2016:00:00:00 17 50 180 3.0 Apr-2021
    S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab SWOG 07FEB2017:00:00:00 7 11 148 1.7 Jul-2024
  II-III NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG 30DEC2016:00:00:00   1   0.2  
  III A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) ALLIANCE 01JUL2015:00:00:00   2   0.0  
    R0924 Pros, NADT+WPRT vs. NADT+P&SV RT NRG 07JUL2011:00:00:00   52   2.0  
    S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG SWOG 07FEB2017:00:00:00 7 32 969 5.2 > 15 Yrs
LEUK I S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP SWOG 01APR2014:00:00:00 41 37 38 0.5 Oct-2017
  I-II S1318 ALL, Age 65+, Ph±, Blinatumomab SWOG 12JAN2015:00:00:00 32 47 44 3.3 Sep-2017
  III E1910 BCR-ABL-neg, B ALL, Blinatumomab ECOG-ACRIN 23DEC2013:00:00:00   66   2.3  
    E2906 AML, Age 60+, Clo vs Dauno+Cy ECOG-ACRIN 24FEB2011:00:00:00   75   0.0  
  OTHER NHLBIMDS LEUK, National MDS Study ECOG-ACRIN 05APR2016:00:00:00   5   0.5  
LUNG I-II 8811 NSCLC, Stage III,ChemoRT+ABT-888 SWOG 02JAN2013:00:00:00 56 53 162 3.2 Jul-2020
  II R1306 NSCLC,Adv,ALK/EGFR,TargetAgents NRG 04NOV2013:00:00:00   8   0.0  
    S1400G HRRD: Talazoparib (BMN 673) SWOG 07FEB2017:00:00:00 7 29 60 4.7 Mar-2018
    S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel SWOG 18JUL2016:00:00:00 14 37 53 2.8 Feb-2018
  II-III NRGCC003 SCLC, PCI or HA-PCI NRG 07DEC2015:00:00:00   4   0.5  
    S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab SWOG 25MAR2015:00:00:00 29 139 605 7.7 Sep-2022
  III A081105 ALCHEMIST1, EGFR mut, Erlotinib ALLIANCE 02JAN2014:00:00:00   25   1.5  
    C30610 SCLC, Thoracic RT ALLIANCE 21MAR2008:00:00:00   52   0.3  
    E4512 ALCHEMIST2, ALK mut, Crizotinib ECOG-ACR 18AUG2014:00:00:00   5   0.3  
    EA5142 ALCHEMIST3, Non-match, Nivolumab ECOG-ACRIN 16MAY2016:00:00:00   22   2.3  
    S1400I Non-Match: Nivo + Ipi vs Nivo SWOG 18DEC2015:00:00:00 21 229 350 8.7 Oct-2018
  OTHER A151216 ALCHEMIST0 - screening ALLIANCE 06FEB2014:00:00:00   365   17.5  
    S1400 SCCA,Adv, Biomarker Master SWOG 15JUN2014:00:00:00 39 1378   30.7  
LYMPH II S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob SWOG 10AUG2017:00:00:00 1 0 150    
  III A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo ALLIANCE 15JUL2016:00:00:00   2   0.3  
MELAN II E3612 MELAN,Adv Ipilimumab±Bevacizumab ECOG-ACR     6      
    S1320 Adv, BRAF mut, Inter v Contin SWOG 22JUL2014:00:00:00 38 171 280 5.7 Apr-2019
    S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) SWOG 20OCT2016:00:00:00 11 3 77 0.3 > 15 Yrs
    S1616 MELAN,, Adv, Ipilimumab ± Nivolumab SWOG 17JUL2017:00:00:00 2 0 94    
  II-III EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 01MAR2016:00:00:00   36   3.0  
  III EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T ECOG-ACR 15DEC2015:00:00:00   19   0.7  
    S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 SWOG 15OCT2015:00:00:00 23 1345 1378 82.0 Sep-2017
MMYEL I-II S1211 MM,High Risk, RVD+/-ELO SWOG 27OCT2012:00:00:00   142 110   Jun-2016 Temp Close
  III E1A11 MM, frontline, BLD vs CLD ECOG-ACRIN 22NOV2013:00:00:00   137   5.2  
OTHER I-II A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II ALLIANCE 26JAN2015:00:00:00   6   0.7  
  II A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo ALLIANCE 02SEP2014:00:00:00   2   0.2  
    A091305 HN, Adv, Thyroid PPAR agonist + Chemo ALLIANCE 01SEP2014:00:00:00   2   0.0  
    A091401 Sarc, ALLIANCE 18JUN2015:00:00:00   5   0.0  
    A091404 HN, AR+, Enzalutamide ALLIANCE 25SEP2015:00:00:00   5   0.7  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   2   0.3  
    NRGBN001 HN, novel vs. std chemoradiation + chemo NRG 28AUG2015:00:00:00   1   0.0  
  II-III G0281 Ovar, Recur/prog LG, IC chemo vs trametinib NRG 27FEB2014:00:00:00   1   0.2  
    G0286B Adv Endometrial,Metformin/Chemo NRG     1      
    NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG 06FEB2016:00:00:00   3   0.2  
    NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG 21APR2014:00:00:00   3   0.2  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   3   0.0  
  III G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT NRG 12APR2010:00:00:00   1   0.2  
    N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC ALLIANCE     4      
    NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo NRG 04FEB2016:00:00:00   4   0.2  
    R0724 Cervical, Chem+RT +/- Adj. Chemo NRG 15JAN2014:00:00:00   1   0.0  
    R0920 HN, Adv, Postop IMRT ± Cetuximab NRG 24DEC2013:00:00:00   10   0.0  
  OTHER EAQ152 Communication & education in tumor profiling ECOG-ACR 26SEP2016:00:00:00   11   0.8  
PREV II EA1141 Breast, Abbrev. MRI vs Digital Tomosynthesis ECOG-ACR 02SEP2016:00:00:00   18   3.0  
  III A211102 Breast, Atypia via RPFNA, Metformin v Placebo ALLIANCE 01FEB2015:00:00:00   3   0.2  
    S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac SWOG 01MAR2013:00:00:00 54 161 480 5.0 Dec-2022
  OTHER A211201 Breast Density, MA.32 companion ALLIANCE 22AUG2012:00:00:00   14   0.0  
SURV III E1Q11 EROS: Reproductive Health in Cancer Survivors ECOG-ACR 30SEP2015:00:00:00   6   0.7  
    S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 0 0 817    
  OTHER S1316 Compar. Effectiv. Trial for MBO SWOG 09MAR2015:00:00:00 30 110 200 7.0 Sep-2018
SXQOL III A221101 Glioma, Nuvigil/Placebo Fatigue ALLIANCE 03JUN2013:00:00:00   17   0.5  
    A221102 Brst,AI Arthralgia,Testosterone ALLIANCE 07SEP2012:00:00:00   10   0.0  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

22-SEP-2017 18:11

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

The REPORT Procedure

Detailed and/or summarized report

Table 1

Phase Comm. Int
grp
Stat
Center
Study NCIPROTO CA
Cntrl
Study
Temp
Close
OTHER BREAST Y ECOG-ACRIN E1Z11 Brst,Genetic Predictors of AIMSS E1Z11 Y  
    Y ALLIANCE A221405 Breast, ET interruption, Pregnancy Outcomes A221405 Y  
  CCD N   S1417CD Colorectal, Cost Cohort Study   Y  
  ERLYTX Y ECOG-ACR EAY131 MATCH EAY131 N  
  LEUK Y ECOG-ACRIN NHLBIMDS LEUK, National MDS Study NHLBI-MDS Y  
  LUNG Y SWOG S1400 SCCA,Adv, Biomarker Master S1400 N  
    Y ALLIANCE A151216 ALCHEMIST0 - screening A151216 N  
  OTHER Y ECOG-ACR EAQ152 Communication & education in tumor profiling EAQ152 Y  
  PREV Y ALLIANCE A211201 Breast Density, MA.32 companion A211201 Y  
  SURV Y SWOG S1316 Compar. Effectiv. Trial for MBO S1316 Y  
I LEUK N   S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP   N  
I-II LEUK Y SWOG S1318 ALL, Age 65+, Ph±, Blinatumomab S1318 N  
  LUNG Y SWOG 8811 NSCLC, Stage III,ChemoRT+ABT-888 8811 N  
  MMYEL Y SWOG S1211 MM,High Risk, RVD+/-ELO S1211 N Y
  OTHER Y ALLIANCE A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II A091304 N  
II BREAST Y SWOG S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 S1416 N  
  ERLYTX Y SWOG S1609 Rare Tumor, Comb Nivo/Ipi S1609 N  
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
  GI Y SWOG S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888 S1513 N  
    Y SWOG S1505 Panc,Resect, Perioperative Chemo S1505 N  
    Y ECOG-ACRIN EA2142 GI NEC, Adv G3, EP vs TMZ + CAP EA2142 N  
    Y NRG NRGGI002 Rectal, Ph II, Sensitization using TNT NRG-GI002 N  
    Y ALLIANCE A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT A021501 N  
    Y ECOG-ACRIN EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo EA2133 Y  
  GU Y SWOG S1314 Blad, COXEN Neoadj. Chemo + Cyst S1314 N  
    Y SWOG S1500 pRCC,Adv, Sunitinib vs MET inhib S1500 N  
    Y SWOG S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab S1605 N  
    Y ECOG-ACR EA8141 UTUC, HG, Chemo then Surg EA8141 N  
  LUNG Y SWOG S1400G HRRD: Talazoparib (BMN 673) S1400G N  
    Y SWOG S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel S1507 N  
    Y NRG R1306 NSCLC,Adv,ALK/EGFR,TargetAgents RTOG-1306 N  
  LYMPH Y SWOG S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob S1608 N  
  MELAN Y SWOG S1320 Adv, BRAF mut, Inter v Contin S1320 N  
    Y SWOG S1616 MELAN,, Adv, Ipilimumab ± Nivolumab S1616 N  
    Y SWOG S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) S1512 N  
    Y ECOG-ACR E3612 MELAN,Adv Ipilimumab±Bevacizumab E3612 N  
  OTHER Y NRG NRGBN001 HN, novel vs. std chemoradiation + chemo NRG-BN001 N  
    Y ALLIANCE A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo A091202 N  
    Y ALLIANCE A091401 Sarc, A091401 N  
    Y ALLIANCE A091305 HN, Adv, Thyroid PPAR agonist + Chemo A091305 N  
    Y ALLIANCE A091404 HN, AR+, Enzalutamide A091404 N  
    Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
  PREV Y ECOG-ACR EA1141 Breast, Abbrev. MRI vs Digital Tomosynthesis EA1141 Y  
II-III ERLYTX Y ALLIANCE A071102 GBM, adj TMZ +/- Veliparib A071102 N  
    Y COG ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) ARST1321 N  
  GI Y ALLIANCE N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX N1048 Y  
  GU Y NRG NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG-GU002 N  
  LUNG Y SWOG S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab S1403 N  
    Y NRG NRGCC003 SCLC, PCI or HA-PCI NRG-CC003 Y  
  MELAN Y ECOG-ACRIN EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG-GY005 Y  
    Y NRG G0286B Adv Endometrial,Metformin/Chemo GOG-0286B Y  
    Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG-HN001 Y  
    Y NRG G0281 Ovar, Recur/prog LG, IC chemo vs trametinib GOG-0281 Y  
III BREAST N   S1222 Brst,Fulv. +/- Ever. +/- Anastr.   N Y
    Y SWOG S1207 Brst,Adj,Endocrine+/-Everolimus S1207 Y  
    Y SWOG S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) S1418 Y  
    Y SWOG S1007 Breast,Adj,N1,Endocrine+/-Chemo S1007 Y  
    Y ALLIANCE A011202 Breast, Nodal XRT +/- ALND A011202    
    Y ALLIANCE A011106 Breast, Neoadj, ALTERNATE study A011106 N  
    Y NRG B51 Breast, Regional Nodal XRT NSABP-B-51 Y  
    Y ALLIANCE A011401 Breast, adj, Stage II/III HER2-, weight loss A011401 Y  
    Y NRG NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG-BR003 N  
    Y ECOG-ACR E2112 Brst,Adv,Exemestane+/-Entinostat E2112 Y  
    Y ALLIANCE A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo A011502 Y  
    Y NRG B55 Brst, Adj Olaparib for BRCA,TNBC NSABP-B-55 Y  
  CCD Y SWOG S1415CD TrACER CSF Standing Order Intervention for FN S1415CD Y  
    Y ALLIANCE A011104 Preoperative Breast MRI A011104 Y  
  GI Y NRG R0848 Panc, Adj, Erlotinib v ChemoRT RTOG-0848 Y  
  GU Y SWOG S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG S1602 Y  
    Y NRG R0924 Pros, NADT+WPRT vs. NADT+P&SV RT RTOG-0924 Y  
    Y ALLIANCE A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) A031102 Y  
  LEUK Y ECOG-ACRIN E2906 AML, Age 60+, Clo vs Dauno+Cy E2906 Y  
    Y ECOG-ACRIN E1910 BCR-ABL-neg, B ALL, Blinatumomab E1910 N  
  LUNG Y SWOG S1400I Non-Match: Nivo + Ipi vs Nivo S1400I Y  
    Y ALLIANCE C30610 SCLC, Thoracic RT CALGB-30610 Y  
    Y ALLIANCE A081105 ALCHEMIST1, EGFR mut, Erlotinib A081105 N  
    Y ECOG-ACRIN EA5142 ALCHEMIST3, Non-match, Nivolumab EA5142 N  
    Y ECOG-ACR E4512 ALCHEMIST2, ALK mut, Crizotinib E4512 N  
  LYMPH Y ALLIANCE A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo A051301 N  
  MELAN Y SWOG S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 S1404 Y  
    Y ECOG-ACR EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T EA6134 Y  
  MMYEL Y ECOG-ACRIN E1A11 MM, frontline, BLD vs CLD E1A11 Y  
  OTHER Y NRG R0920 HN, Adv, Postop IMRT ± Cetuximab RTOG-0920 Y  
    Y ALLIANCE N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC N0577 N  
    Y NRG G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT GOG-0263 Y  
    Y NRG R0724 Cervical, Chem+RT +/- Adj. Chemo RTOG-0724 Y  
    Y NRG NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo NRG-GY004 Y  
  PREV Y SWOG S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac S0820 Y  
    Y ALLIANCE A211102 Breast, Atypia via RPFNA, Metformin v Placebo A211102 Y  
  SURV Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
    Y ECOG-ACR E1Q11 EROS: Reproductive Health in Cancer Survivors E1Q11 Y  
  SXQOL Y ALLIANCE A221101 Glioma, Nuvigil/Placebo Fatigue A221101 Y  
    Y ALLIANCE A221102 Brst,AI Arthralgia,Testosterone A221102 Y  
    Y NRG NRGBR002 NRG-BR002    

22-SEP-2017 18:11

PHASE III SWOG COORDINATED OPEN STUDIES

SORTED BY STUDY ID

The REPORT Procedure

Detailed and/or summarized report

Table 1

Protocol
Number
Study Accrual
Goal
Open
Stat/Date
Months
Open
Accrual
as of
01Jan02
Current Accrual Proj.
Annual
Accr.
Rate
EXPCLOSE Proj.
Study
Duration
(Years)
S0820 S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac (PREV) 480 Y-03/01/13 54 161 161 60 Dec-2022 9.8
S1007 S1007 Breast,Adj,N1,Endocrine+/-Chemo (BREAST) 4000 Y-01/15/11 80 5047 5047 516 Sep-2015 4.7
S1207 S1207 Brst,Adj,Endocrine+/-Everolimus (BREAST) 1900 Y-09/03/13 48 1356 1356 430 Dec-2018 5.3
S1222 Brst,Fulv. +/- Ever. +/- Anastr. (BREAST) 840 T-05/09/14 40 37 37 0 > 15 Yrs > 15 Yrs
S1400I S1400I Non-Match: Nivo + Ipi vs Nivo (LUNG) 350 Y-12/18/15 21 229 229 104 Oct-2018 2.8
S1403 S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab (LUNG) 605 Y-03/25/15 29 139 139 92 Sep-2022 7.5
S1404 S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 (MELAN) 1378 Y-10/15/15 23 1345 1345 984 Sep-2017 1.9
S1415CD S1415CD TrACER CSF Standing Order Intervention for FN (CCD) 3960 Y-09/01/16 12 895 895 1324 Dec-2019 3.3
S1418 S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) (BREAST) 1000 Y-11/15/16 10 66 66 122 Apr-2025 8.4
S1501 S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol (SURV) 817 Y-09/15/17 0 0 0      
S1602 S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG (GU) 969 Y-02/07/17 7 32 32 62 > 15 Yrs > 15 Yrs
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.